

Should Remdesivir Be Used for the Treatment of Patients with COVID-19? Rapid, Living Practice Points from the American College of Physicians (2022)

The American College of Physicians issued its fifth and final living, rapid Practice Points regarding the use of remdesivir in hospitalized patients with COVID-19. The updated Practice Points are based on a review of the most up-to-date published data available on the benefits and harms of remdesivir and whether those benefits and harms vary by symptom duration, disease severity, and treatment duration.

Published online June 18, 2020 *Annals of Internal Medicine* full text:
<https://www.acpjournals.org/doi/10.7326/M20-5831>

Published online February 9, 2021 Update Alert: *Annals of Internal Medicine* full text:
<https://www.acpjournals.org/doi/10.7326/M20-8101>

Published online July 2021 Update Alert: *Annals of Internal Medicine* full text:
<https://www.acpjournals.org/doi/10.7326/L21-0389>

Published online October 2021 Update Alert: *Annals of Internal Medicine* full text:
<https://www.acpjournals.org/doi/10.7326/L21-0607>

Published online February 2022 Update Alert: Retired from Living Status *Annals of Internal Medicine* full text: <https://www.acpjournals.org/doi/10.7326/M21-4784>